Rhizen Pharmaceuticals S.A. to present preclinical data of their first-in-class inflammation assets, RP6503 and RP3128 for treatment of various respiratory diseases

        Print
| Source: Rhizen Pharmceuticals SA

La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead first-in-class inflammation/auto-immune assets, RP6503 and RP3128 in preclinical models of pulmonary fibrosis, COPD and asthma.   Therapeutic potential of RP3128 in asthma will be highlighted during an oral presentation.

--- Data to be presented at European Respiratory Society (ERS) International Congress 2014, September 6-10, Munich, Germany

--- RP-6503, a novel dual PI3K delta/gamma inhibitor demonstrated potent anti-inflammatory and anti-fibrotic data especially in combination with Esbriet ®  (pirfenidone) in preclinical models of pulmonary fibrosis

--- RP-6503, a novel dual PI3K delta/gamma inhibitor demonstrated significant efficacy in preclinical models relevant to COPD

--- Oral administration of RP-3128, a potent and novel CRAC channel inhibitor attenuated respiratory distress in allergen challenged guinea pig models 

--- Phase 1 clinical trials (inhalation & oral route) to be initiated in 1H of 2015

Details of the poster and oral presentations:

-- Poster Title:  Pre-clinical evaluation of a novel and selective PI3K delta/gamma inhibitor in pulmonary fibrosis

·      Session:                              160

·      Presentation Date & Time: 07 September 2014; 14:45-16:45

·      Session Location:               Room M-1(B0)

·      Poster Board Number:        P1507

-- Poster Title:  RP-6503, a novel and selective PI3K delta/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD

·      Session Information:          160

·      Presentation Date & Time: 07 September 2014; 14:45-16:45

·      Session Location:               Room M-1(B0)

·      Poster Board Number:        P1504

-- Oral Presentation Title:  CRAC channel inhibition by RP3128 ameliorates airway hyper-reactivity in antigen sensitized mice and guinea pigs 

·      Session:                               508                

·      Presentation Date & Time: 10 September 2014; 10:45-12:45

·      Presentation Location:        Room 14c (ICM)                   

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders.  Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.  Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland.  For additional information, please visit Rhizen's website, www.rhizen.com.

Kumar V. Penmetsa, Ph.D.
Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone:  +1-267-207-5707
Email: